GNPX vs. TCRT, KALA, AYTU, TLPH, GLYC, GLTO, NERV, TNXP, FLGC, and ORGS
Should you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Alaunos Therapeutics (TCRT), KALA BIO (KALA), Aytu BioPharma (AYTU), Talphera (TLPH), GlycoMimetics (GLYC), Galecto (GLTO), Minerva Neurosciences (NERV), Tonix Pharmaceuticals (TNXP), Flora Growth (FLGC), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical preparations" industry.
Genprex (NASDAQ:GNPX) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.
In the previous week, Alaunos Therapeutics had 1 more articles in the media than Genprex. MarketBeat recorded 3 mentions for Alaunos Therapeutics and 2 mentions for Genprex. Alaunos Therapeutics' average media sentiment score of 1.25 beat Genprex's score of 0.94 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.
Genprex received 192 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 65.25% of users gave Genprex an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote.
Alaunos Therapeutics' return on equity of -229.55% beat Genprex's return on equity.
14.1% of Genprex shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 11.5% of Genprex shares are held by insiders. Comparatively, 5.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Genprex has a beta of -0.54, indicating that its share price is 154% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500.
Genprex presently has a consensus price target of $10.00, indicating a potential upside of 346.43%. Given Genprex's stronger consensus rating and higher probable upside, research analysts clearly believe Genprex is more favorable than Alaunos Therapeutics.
Summary
Genprex beats Alaunos Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Genprex News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
